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Introduction: microRNAs (miRNAs), small noncoding RNAs, are deregulated in
several diseases including cancer. miRNAs regulate gene expression at a post-
transcriptional level by binding to 5¢UTR, coding regions or 3¢UTR of messenger
RNAs (mRNA), inhibiting mRNA translation or causing mRNA degradation. The
same miRNA can have multiple mRNA targets, and the same mRNA can be
regulated by various miRNAs.
Areas covered: Recently, seminal contributions by several groups have impli-
cated miRNAs as components of an RNA--RNA language that involves cross-
talk between competing endogenous RNAs through a decoy mechanism.
We review the studies that described miRNAs as players in a biological decoy
activity. miRNAs can either be trapped by competing endogenous RNAs or
interact with proteins that have binding sites for mRNAs.
Expert opinion: The miRNA decoy functions have implications for the
design of therapeutic approaches in human diseases, including specific ways
to overcome resistance to drug therapy and future miRNA-based clinical
trials design.
Keywords: mimic, regulation, sponge, therapeutic potential
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1. Introduction
Contrary to the case with protein-coding genes, there is a proportional increase between
the number of noncoding transcripts (ncRNA, RNAs that do not codify for proteins
but influence by variousmechanisms their expression and function) and the complexity
among the species [1,2], with the ratio of noncoding to coding sequences being about
47:1 in humans [3]. The use of massively parallel sequencing platforms of “next-
generation sequencing,” with use of the RNA sequencing (RNA-seq) application,
revealed thousands of transcripts and opened the door to a comprehensive study of
the nonprotein-coding transcriptome [4,5]. Up to 97% of the human genome consists
of nonprotein-coding DNA [6], and noncoding transcripts comprise a heterogeneous
group that includes, among other, microRNAs (miRNAs), small nucleolar RNAs
(snoRNAs), infrastructural RNAs (ribosomal RNA [rRNA], transfer RNAs [tRNAs],
and small nuclear RNAs [snRNAs]), long intergenic noncoding RNAs (lincRNAs),
antisense transcripts, noncoding transcribed ultraconserved regions, and promoter
upstream transcripts (PROMPTs) [7]. The ncRNAs can be intergenic or can overlap
with the coding regions loci, being antisense or intronic [2]. The paradigm of RNA as
a mere intermediary between DNA and protein became obsolete when it became
evident that the previously called “junk” DNA [8] could be of major importance for
biologic diversity [5] and may have key biological functions [9]. Although much
still needs to be studied about the function of ncRNAs, the top of the iceberg is
being revealed as we increase our understanding of the importance of ncRNAs in the
regulation of gene expression.
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In this review, we intend to focus on the studies that identi-
fied the miRNA decoy activity, and we propose to emphasize
the potential significance of these studies for therapy.
2. Current evidence
miRNAs are small ncRNAs, approximately 20 nucleotides
long, that control gene expression at a posttranscriptional level
by mRNA degradation or translation inhibition, through the
binding to 5´UTR, coding sequences, or 3´UTR of target
mRNAs [10]. miRNAs can regulate multiple target genes, and
simultaneously, target genes can be regulated by multiple miR-
NAs. Victor Ambros’ and Gary Ruvkun´s groups first discov-
ered miRNAs in 1993 as a new mechanism of gene regulation
inCaenorhabditis elegans [11,12]. In 2000, Pasquinelli et al. proved
that let-7 was conserved among species, opening the door for the
study of miRNAs in humans [13]. Later, in 2002, it was reported
thatmiRNAswere deregulated in cancer [14]. To date, thousands
of studies have analyzed the expression of miRNAs and
its role in cancer and in cardiovascular, autoimmune, and
neurodegenerative diseases [10].
Recently, another function for miRNAs was found: the
decoy activity. In early 2010, Perrotti´s group reported the par-
adigm shift in miRNA function [15]. hnRNP E2 is a member of
the family of RNA-binding proteins whose members are
involved in mRNA processing, nucleocytoplasmic export, and
translation of mRNAs [16]. In cells in which the BCR/ABL
oncogene is expressed, causing an arrest of differentiation in
myeloid blast crisis chronic myelogenous leukemia, there is an
increase of hnRNP E2 protein [17]. hnRNP E2 interacts with
the transcription factor CEBPA, inhibiting the translation of
mRNA. Using RNA electrophoretic mobility shift assays, UV
crosslinking, and RNA immunoprecipitation assays, the
authors found that miR-328 (that is downregulated in a
BCR/ABL-dependent manner) competes with CEBPA mRNA
for the hnRNP E2 binding site [15]. They also proved that
restoration of miR-328 expression interferes with hnRNP
E2 function of translation inhibition by preventing CEBPA::
hnRNPE2 binding and consequently restores, in vivo and
in vitro, CEBPA mRNA translation [15] (Figure 1A). Besides
the decoy activity, miR-328 also functions in the canonical
way by suppressing translation of mRNA encoding the
PIM1 protein kinase through base pairing interaction [15].
Later the same year, Poliseno et al. reported in Nature the
intriguing discovery that pseudogenes could function as a decoy
for miRNAs’ effects on corresponding protein-coding genes [9].
The authors used as a model the well-known tumor suppressor
PTEN and its pseudogene PTENP1, which has a high sequence
homology with part of the PTEN 3´UTR [9]. The authors proved
that PTENP1 is targeted by some of the miRNAs that target
also PTEN, including miR-19b and miR-20a. Through a
miRNA-dependent mechanism, overexpression of PTENP1
3´UTR resulted in the derepression of PTEN (and consequently
proved that PTENP1 has a role as a tumor suppressor), and
expression of PTEN 3´UTR resulted in the derepression of
PTENP1 [9]. In addition, the authors showed that the same decoy
mechanism is present when analyzing other genes and their
related pseudogenes, such as the KRAS gene and its pseudogene
KRAS1P [9]. This new concept was further developed 1 year later,
when the same group showed that not only noncoding genes can
compete for miRNAs binding sites, but also protein-coding
transcripts can compete with one another [18]. Transcripts that
have the same miRNA binding sites (or miRNA response ele-
ments [MREs]) are called “competing endogenous RNAs” (ceR-
NAs) [19] and may act as natural miRNA sponges. The authors
used bioinformatics (MRE enrichment----MuTaME----analysis)
and biological approaches to validate ceRNA for PTEN [18].
Some of these mRNAs are SERINC1, VAPA, and CNOT6L,
whose expression in human prostate cancer and glioblastoma
samples was significantly different between PTEN-high and
PTEN-low groups [18]. In addition, silencing of these ceRNAs
resulted in a decrease in luciferase activity when cells were
co-transfected with a luciferase vector containing the PTEN 3´
UTR.The authors further proved that this correlationwas depen-
dent on the miRNAs, since regulation of PTEN expression by
SERINC1, VAPA, and CNOT6L ceRNAs vanished in the cells
with a defect in themiRNAprocessingmachinery [18] (Figure 1B).
In the same issue of Cell, three articles reported “out-of-the-
box” discoveries about coding transcripts and competing
endogenous RNAs. Sumazin et al. used a multivariate analysis
method, named Hermes, to combine gene expression data
with miRNA profiles in glioblastoma and found 7,000 genes
whose transcripts were involved in sponge regulatory interac-
tions (modulator and sponges share miRNAs binding sites)
and 148 genes that were involved in nonsponge regulatory
interactions (modulator and sponges that do not necessarily
share miRNA binding sites) [20]. Moreover, the authors
focused on the PTEN transcript to perform validation
Article highlights.
. RNA transcripts that have the same specific miRNA
binding sites can compete for miRNAs binding.
. miRNAs can be trapped by ceRNAs that function as
natural miRNA sponges.
. miRNAs function as RNA decoys upon interaction with
heterogeneous ribonucleoproteins, as hnRNP (that have
binding sites for mRNAs).
. Decoy mechanisms involving miRNAs and the balance
between levels of specific ceRNAs should be considered
when designing new therapeutic approaches aiming to
correct gene expression.
. The hypothesis that miRNA-based decoy mechanisms
play a role in the resistance to therapy is worthy of
being explored.
. For therapeutic approaches using precursor microRNAs,
when two mature forms are processed, their expression,
function and mRNA targets should be considered, as
some of these could be ceRNAs for both 3p and 5p of
that specific miRNA.
This box summarizes key points contained in the article.
M. I. Almeida et al.
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studies for PTEN miRNA-mediated decoy in glioblastoma
cell lines [20].
In another study, Karreth et al. identified PTEN ceRNAs in
a mouse model of melanoma with use of the sleeping beauty
transposon system [21]. The authors further validated ZEB2 as
a ceRNA decoy for PTEN by demonstrating that ZEB2
depletion downregulates PTEN and that this reduction was
dependent on the 3´UTR (ZEB depletion suppressed luci-
ferase activity of PTEN 3´UTR reporter) and on miRNAs
(ZEB2 depletion does not reduce PTEN expression in cells
with a defect in the miRNA processing machinery) [21]. Finally,
Cesana et al. reported that a long noncoding RNA, linc-MD1,
acts as a ceRNA for MAML1 and MEF2C mRNAs, two tran-
scription factors that regulate muscle-specific genes, by interact-
ing with miR-133 and miR-135, thereby regulating muscle
differentiation [22].
All of the above-mentioned studies were crucial to a new
understanding of the importance of miRNAs in mediating
mRNA decoys, and their significance has been highlighted
in several articles. For example, McCarthy [23] stated that a
subtle reduction in few mRNA could cause widespread
effects. Rigoutsos and Furnari [24] indicated that the relative
amount of mRNAs and corresponding ceRNAs should be
considered and they introduced the intriguing hypothesis
that the decoy mechanism may also occur in cases in which
PTEN levels are reduced without mutation, such as in Cow-
den disease and Bannayan-Zonana syndrome. In addition,
Swami [25] questioned how this decoy applied in noncancer-
related genes. In the “Expert Opinion” section, we give our
opinion from a therapeutic point of view.
3. Expert opinion: potential therapeutic
consequences
The capacity of multiple mRNAs to compete for available
miRNAs introduces a new challenge for miRNA-based
‘Double decoy’
hypothesisIn CML-BC
miR-328
CEBPA translation 
suppression
Differentiation 
arrest
miR-328 and CEBPA compete 
for hnRNPE2 binding
Decoy activity
miR-328
hnRNP E2
CEBPA mRNA
hnRNP E2
::
CEBPA mRNA
CEBPA translation
Differentiation
miR-328 decoy
hnRNP E2
::
miR-328
ceRNAs – PTEN gene and 
PTENP1 pseudogene
RNA transcript A
Responsive element Y
RNA transcript B
Responsive element Y
microRNA Y
PTENP1
PTEN::miRNA
PTEN
Increased 
proliferation
PTENP1 3′UTR
PTEN::miRNA 
derepression
PTEN
Decreased 
proliferation
A. B. C. 
Competitive endogenous RNAs
(RNA transcripts with responsive
element Y)  
RNA-binding proteins
microRNA Y
interacts with
miRNA-associated decoy
mechanisms 
Figure 1. The decoy by microRNAs. A. miR-328 decoy. In blast crisis chronic myelogenous leukemia (CML-BC), miR-328 is
downregulated. The RNA binding protein hnRNP E2 interacts with CEBPA mRNA, suppressing it translation and causing a
differentiation arrest. When miR-328 restoration is induced, miR-328 interacts with hnRNP E2, releasing CEBPA from the translation
inhibitory effects of hnRNAPE2 and leading toCEBPAmRNA translation.B. Complementary endogenous RNAs (ceRNAs) -- PTENgene
andpseudogene.Thebasicprincipleof ceRNAis thatdifferentRNAs (e.g.,RNAtranscriptAandRNAtranscriptB) that contain thesame
microRNA binding sites (e.g., responsive element Y) can compete with each other for those microRNAs (e.g., microRNA Y). The first
example of ceRNAs was the PTEN gene and it pseudogene PTENP1, that share samemicroRNA responsive elements. When PTENP1 is
silenced, the tumor suppressor PTEN is decreased leading to an increase in cell proliferation. Accordingly, when PTENP1 3C¸UTR is
overexpressed, PTEN levels increaseddue toadecoy for themicroRNAs, causingadecrease in cell proliferation.C. Thehypothesis states
that the same miRNA can be trapped between binding to proteins and to ceRNAs. This represents a combination of the two
experimentally identified instances presented in (A) and (B). WhenmiRNA Y interacts with an RNA binding protein, the effect of this
interaction on the competingmRNA species could be variable. In the case ofmiR-328 and hnRNP E2, the interaction ofmiRNAYwith
the protein induces mRNA translation. However, one could hypothesize that interaction of miRNA Y with a protein that stabilizes
mRNAs and induces translation (e.g. hnRNPA1) could result in reducedexpressionofmRNAcontaining the samemiRNAbinding sites.
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cancer therapies because the expression levels of the several
transcripts regulated by the miRNAs need to be specifically
taken into account. miRNAs have been suggested not only
as therapeutic targets in several diseases but also as therapeutic
tools because miRNAs can regulate the protein expression of
major genes involved in disease and therefore influence
patient outcome. There are two major strategies to modulate
miRNA expression and consequently influence gene expres-
sion: miRNA antagonists (e.g., to knock down miRNA onco-
genic activity) and miRNA mimics (e.g., to restore miRNA
tumor suppressor activity). The decrease in miRNA levels
may be achieved by using chemically modified antisense
oligonucleotides such as 2´-O-methyl, 2´-O-methoxyethyl,
morpholino oligomers and locked nucleic acid (LNA) [26].
All of these molecules function as miRNA sponges, since
they are designed to be complementary to miRNAs and to
sequester miRNAs and derepress the mRNA targets. Studies
have indicated that research using LNAs (first described in
the late 1990s) is quickly progressing. miR-122 reduction
using LNA (complementary with miR-122 sequence) was
tested in primates [27]. Lanford et al. successfully suppressed
chronic hepatitis C virus infection in chimpanzees by using
LNA against miR-122 and obtained long-lasting but no
secondary effects [27]. In contrast to the chemically engineered
antagomirs, ceRNAs function as natural biological sponges.
In the case of PTEN and its pseudogene PTENP1, if we
could therapeutically overexpress the pseudogene, PTEN
would be automatically derepressed since miRNAs would
bind mainly to the pseudogene. If we could modulate the
levels of ceRNAs, we could restore the expression of a full
network of mRNA through miRNAs interaction. It is
therefore crucial, when deciding on a therapeutic approach
involving miRNAs, to consider not only the miRNA levels
in that specific cancer, but also the expression balance between
the levels of the ceRNAs. In addition, not only the amount of
transcripts but also the stability of the miRNA::mRNA bind-
ing should be analyzed. Furthermore, in light of the Perrotti
group’s publication, the same miRNA could bind both ceR-
NAs and also proteins with binding sites for specific mRNAs
(maybe themselves ceRNAs). This introduces another level of
complexity since, for example, hnRNPs are members of a
large family of proteins that are usually highly overexpressed
in human cancers [15] and therefore could easily trap the
interactor miRNAs (Figure 1C).
It is well known that miRNAs are involved in drug resis-
tance [28]. An unexpected consequence of the ceRNA concept
is the fact that resistance to therapy can be caused by an abnor-
mal balance between the ceRNA network components. For
example, the cancer-specific overexpression of pseudogene(s)
of a gene involved in blocking the activity of a drug can “trap”
miRNA molecules that otherwise in normal cells would bind to
and downregulate the specific drug-resistance gene. In this case,
the gene involved in blocking the activity of a drug would be
translated causing drug resistance. Indeed, if a miRNA that
targets genes inducing drug resistance is trapped by ceRNAs,
it is expected that the mRNAs involved in drug resistance are
derepressed, which would contribute to increased resistance
to specific drugs. Also, the opposite mechanism can be
postulated -- the release of miRNAs that target genes involved
in the induction of cell death by the drug, due to downregula-
tion of ceRNAs. This will lower the malignant cell sensitivity to
drug with consequent increased cell survival and resistance to
particular chemotherapeutic regimens. Therefore, in cancer
cells, the interactor miRNAs are “used” by the interaction
with the multiple ceRNA messengers instead of directly
targeting and consequently downregulating the coding genes
(Figure 2). The mechanisms of ceRNA expression variation
are the well-known ones for any coding or noncoding gene:
genomic deletions or amplifications, chromosome transloca-
tions, loss-of-function or gain-of-function mutations or pro-
moter methylation. Of course, in the absence of experimental
proof on the therapeutic consequences of ceRNAs, this is a
hypothesis, but one well worth exploring!
Finally, another intriguing possibility is the fact that the
two distinct miRNAs generated from the same hairpin pre-
cursor can function as a decoy if they share also common tar-
gets. This could profoundly influence the design of clinical
studies involving miRNA-based therapy. Although studies
involving miRNA inhibitors are already being developed in
primates, efforts to apply miRNA mimics to therapy are pro-
gressing more slowly. One important aspect to consider when
designing therapeutic approaches for miRNA mimics is the
fact that precursor miRNAs can generate two different mature
miRNAs, -5p and -3p, depending on the hairpin stem-
loop strand of the precursor miRNA, which may have cooper-
ative or different functions. This is the case of miR-28, which
we recently reported to be downregulated in colon cancer [29].
We reported that miR-28-5p, but not miR-28-3p, affects
colon cancer cell proliferation by increasing apoptosis and
causing G1 arrest. On the other hand, miR-28-5p decreases
while miR-28-3p increases colon cancer cells migration and
invasion. These differential effects are partially explained
by the different mRNA targets. In vivo, we observed that
miR-28 expression disrupts tumor growth but increases
metastasis [29]. Furthermore, we identified several common
mRNA targets that are predicted to interact in independent
sites for 5p and 3p miR-28, sometimes separated only
by few nucleotides. Similarly, Jiang et al. reported that
miR-125a-5p and miR-125a-3p, which are downregulated
in non-small cell lung cancer, have opposite effects in vitro
on invasion and migration in cells of this tumor type [30].
Consequently, when designing vectors using precursor
miRNA, it is essential to consider the function of both -5p
and -3p mature forms because one of the strands may cause
adverse effects. Furthermore, the main challenge for miRNA
mimics will be the in vivo delivery strategies. Since the ceRNA
mechanism suggests the existence of multiple miRNAs that
target simultaneously the same spectrum of coding genes
and pseudogenes/other ncRNAs, the 5p/3p pairs of miRNAs
could represent examples of such decoy miRNAs.
M. I. Almeida et al.
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4. Conclusion
One of the main challenges for application of miRNA-
based therapies is the in vivo delivery method. In most cases,
the delivery should be tissue-specific (and in some cases,
even cell type-specific); in addition, the secondary undesirable
effects should be controlled and the effect produced should be
stable and long-lasting. Furthermore, the ceRNAs network
and the expression levels of ceRNAs should be considered
when designing the therapeutic approach for a particular
miRNA-target gene.
In conclusion, it seems to be a question of time until miRNA-
based therapies can be used to treat cancer as well as cardiovascu-
lar, inflammatory, and neurodegenerative diseases. Until then,
efforts should be made to solve all of the above-mentioned issues.
It is expected that in the next few years, similar to what happened
in themiRNAs field, a second boon in the long noncodingRNAs
field will emerge and additional functions for these genes will be
revealed. This is the case, for example, of regions in the genome
that have a high level of homology and conservation between
species and whose ultraconserved transcripts have been shown
to be deregulated in cancer [31] but whose function has not yet
been described. Certainly, the efficiency of ceRNA effects
in vivo and the simplicity of this powerful concept remind us
that the ncRNA El Dorado is a land where both scientists and
clinicians should step without dogmas set in stone, but instead
should be ready to accommodate new ideas that could benefit
the people who need them at most ----the patients!
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